Using the standard dose of dapagliflozin employed in this study (2.5 mg/mg), we then demonstrated that it significantly lowered blood glucose (Supplementary Fig. 2b) and insulin concentrations (Fig. 2a), resulting in a reduction in tumor glucose uptake (Fig. 2b) when administered acutely (without differences in body weight). This evidence concerns the gene INS and neoplasm.